Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,568.56 -26.07 (-0.57%) Dow
36,155.93 -89.57 (-0.25%) Nasdaq
14,179.14 -125.89 (-0.88%) Bitcoin USD
41,605.91 +2,075.94 (+5.25%) CMC Crypto 200
855.62 -3.09 (-0.36%)
Lyell Immunopharma, Inc. (LYEL)
| Previous close | 1.9100 |
| Open | 1.9200 |
| Bid | 1.9800 x 1100 |
| Ask | 1.9900 x 800 |
| Day's range | 1.8800 - 2.1250 |
| 52-week range | 1.3200 - 4.0400 |
| Volume | |
| Avg. volume | 900,711 |
| Market cap | 497.441M |
| Beta (5Y monthly) | -0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
GlobeNewswireLyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma. “There remains a high unmet medi
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinical data from two clinical-stage product candidates in 2024Entered into proof-of-concept manufacturing collaboration with Cellares for CAR T cell product candidatePresented six abstracts at SITC highlighting innovations designed to shorten TIL manufacturing, new
- GlobeNewswire
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
